___

• 1. Alp E, Perçin D, Çolakoğlu S et al. Molecular cha- racterization of carbapenem-resistant Klebsiella pneumoniae in a tertiary university hospital in Turkey, J Hosp Inf ect 2013;84(2):178-80. http://dx.doi.org/10.1016/j.jhin.2013.03.002 PMid:23623803 2. Aydın MD. Neisseria gonorrhoeae suşlarında antibiyotik direnci ve beta-laktamaz üretimi: 1996- 2001, ANKEM Derg 2002;16(4):481-5. 3. Baykal A, Çöplü N, Şimşek H, Esen B, Gür D. Kan izolatı E.coli ve K.pneumoniae suşlarında genişle- miş spektrumlu beta-laktamaz, KPC-tip karbape- nemaz ve plazmid aracılı AmpC beta-laktamaz varlığının araştırılması, Mikrobiyol Bul 2012;46(2): 159-69. PMid:22639305 4. Bergen PJ, Landersdorfer CB, Lee HJ, Li J, Nation RL. ‘Old’ antibiotics for emerging multidrug- resistant bacteria, Curr Opin Inf ect Dis 2012;25(6): 626-33. http://dx.doi.org/10.1097/QCO.0b013e328358afe5 PMid:23041772 5. Boucher HW, Talbot GH, Benjamin DK Jr et al. 10 x ‘20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America, Clin Inf ect Dis 2013;56(12):1685-94. http://dx.doi.org/10.1093/cid/cit152 PMid:23599308 6. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! an update from the Infectious Diseases Society of America, Clin Inf ect Dis 2009;48(1):1-12. http://dx.doi.org/10.1086/595011 PMid:19035777 7. Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indicati- ons, and outcomes, Gastrointest Endosc 2013. http://dx.doi.org/10.1016/j.gie.2013.03.1329 8. Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infecti- ons in US intensive care units, 1997-2007, JAMA 2009;301(7):727-36. http://dx.doi.org/10.1001/jama.2009.153 PMid:19224749 9. Bush K. Improving known classes of antibiotics: an optimistic approach for the future, Curr Opin Pharmacol 2012;12(5):527-34. http://dx.doi.org/10.1016/j.coph.2012.06.003 PMid:22748801 10. Chiou CC. Does penicillin remain the drug of cho- ice for pneumococcal pneumonia in view of emer- ging in vitro resistance?, Clin Inf ect Dis 2006;42(2): 234-7. http://dx.doi.org/10.1086/499596 PMid:16355334 11. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement. CLSI Document M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA. (2008). 12. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Nineteenth Informational Supplement. CLSI Document M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA. (2009). 13. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. CLSI Document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA. (2010). 14. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement. CLSI Document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA. (2013). 15. Çağdas U, Otağ F, Tezcan S, Sezgin O, Aslan G, Emekdaş G. Mide biyopsi örneklerinden Helicobacter pylori’nin tanımlanması ve antimik- robiyal direncinin araştırılması, Mikrobiyol Bul 2012;46(3):398-409. PMid:22951652 16. Çıkman A, Ceylan MR, Parlak M, Karahocagil MK, Berktaş M. İmipeneme dirençli Acinetobacter baumannii izolatlarında kolistin-ampisilin/sul- baktam kombinasyonu etkinliğinin değerlendiril- mesi, Mikrobiyol Bul 2013;47(1):147-51. http://dx.doi.org/10.5578/mb.4523 PMid:23390912 17. Demir T, Büyükgüçlü T. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey, Int J Inf ect Dis 2013. http://dx.doi.org/10.1016/j.ijid.2013.04.005. 18. Doğan Ö, Gülmez D, Hasçelik G. Effect of new breakpoints proposed by Clinical and Laboratory Standards Institute in 2008 for evaluating penicil- lin resistance of Streptococcus pneumoniae in a Turkish University Hospital, Microb Drug Resist 2010;16(1):39-41. http://dx.doi.org/10.1089/mdr.2009.0084 PMid:19916790 19. EUCAST. http://www.eucast.org/clinical-break- points/. Erişim tarihi: 14.07.2013. (2013). 20. FDA. http://www.fda.gov/BiologicsBloodVacci- nes/NewsEvents/WorkshopsMeetingsConferen- ces/ucm357258.htm. Erişim tarihi: 14.07.2013. (2013). 21. Fruciano DE, Bourne S. Phage as an antimicrobial agent: d’Herelle’s heretical theories and their role in the decline of phage prophylaxis in the West, Can J Inf ect Dis Med Microbiol 2007;18(1):19-26. PMid:18923687 PMCid:PMC2542891 22. Goossens H. Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group, Clin Microbiol Inf ect 2003;9(9):980-3. http://dx.doi.org/10.1046/j.1469-0691.2003.00690.x PMid:14616692 23. Gülmez D, Gür D. Hacettepe Üniversitesi İhsan Doğramacı Çocuk Hastanesi’nde 2000-2011 yılları arasında kan kültürlerinden izole edilen mikroor- ganizmalar: 12 yıllık değerlendirme, J Pediatr Inf 2012;6(13):679-83. 24. Gülmez D, Gür D, Hasçelik G and EARRS Türkiye Çalışma Grubu. EARSS Türkiye verileri: 2009 Yılı, 1. Ulusal Klinik Mikrobiyoloji Kongresi Kitabı, Antalya (2011). PMCid:PMC3183643 25. Gülmez D, Gür D, Hasçelik G and EARRS Türkiye Çalışma Grubu. Kandan izole edilen Escherichia coli suşlarında antimikrobiyal duyarlılık: EARSS 2003-2009, 34. Türk Mikrobiyoloji Kongresi Kitabı, Girne (2010). 26. Gülmez D, Gür D, Hasçelik G and EARRS Türkiye Çalışma Grubu. Kandan izole edilen Staphylococus aureus suşlarında antimikrobiyal duyarlılık: EARSS 2003-2008 Türkiye verileri, Gülhane Mikrobiyoloji Günleri: Antimikrobiyal Direnç Kitabı, s.217, İstanbul (2010). 27. Gülmez D, Gür D, Hasçelik G and EARRS Türkiye Çalışma Grubu. Türkiye’de kandan izole edilen Klebsiella pneumonia suşlarında antimikrobiyal duyarlılık: EARSS 2006-2009 verileri, Antimikrobik Kemoterapi Laboratuvar Uygulamaları ve Yenilikler Kitabı, s.195-6, İstanbul (2012). 28. Gülmez D, Gür D, Hasçelik G and EARSS-Turkish Study Group. Trends in antimicrobial resistance in invasive isolates of Streptococcus pneumoniae in Turkey (2003-2008), 20th European Congress of Clinical Microbiology (ECCMID) Kitabı, P1685, Viyana (2010). 29. Gülmez D, Woodford N, Palepou MF et al. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membra- ne protein loss, Int J Antimicrob Agents 2008; 31(6):523-6. http://dx.doi.org/10.1016/j.ijantimicag.2008.01.017 PMid:18339523 30. Henry M, Debarbieux L. Tools from viruses: bac- teriophage successes and beyond, Virology 2012;434(2):151-61. http://dx.doi.org/10.1016/j.virol.2012.09.017 PMid:23063405 31. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility, J Antimicrob Chemother 1997;40(1): 135-6. http://dx.doi.org/10.1093/jac/40.1.135 PMid:9249217 32. IDSA. Bad Bugs, No Drugs. As Antibiotic Disco- very Stagnates a Public Health Crisis Brews. Infectious Diseases Society of America (2004). 33. IDSA. http://www.idsociety.org/Patient_Stories/. Erişim tarihi: 14.07.2013. (2013). 34. Johnsen PJ, Townsend JP, Bohn T, Simonsen GS, Sundsfjord A, Nielsen KM. Retrospective eviden- ce for a biological cost of vancomycin resistance determinants in the absence of glycopeptide selec- tive pressures, J Antimicrob Chemother 2011; 66(3):608-10. http://dx.doi.org/10.1093/jac/dkq512 PMid:21217128 PMCid:PMC3037156 35. Johnson AP. Methicillin-resistant Staphylococcus aureus: the European landscape, J Antimicrob Chemother 2011;66(Suppl 4):iv43-8. http://dx.doi.org/10.1093/jac/dkr076 PMid:21521706 36. Kallen AJ, Mu Y, Bulens S et al. Health care- associated invasive MRSA infections, 2005-2008, JAMA 2010;304(6):641-8. http://dx.doi.org/10.1001/jama.2010.1115 PMid:20699455 37. Kuşçu F, Öztürk DB, Gürbüz Y, Tütüncü EE, Şencan I, Gül S. Metisiline dirençli stafilokoklarda azalmış vankomisin duyarlılığının araştırılması, Mikrobiyol Bul 2011;45(2):248-57. PMid:21644067 38. Lawley TD, Clare S, Walker AW et al. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relap- sing Clostridium difficile disease in mice, PLoS Pathog 2012;8(10):e1002995. http://dx.doi.org/10.1371/journal.ppat.1002995 PMid:23133377 PMCid:PMC3486913 39. Levent BR, Güleşen H, Kalaycıoğlu FS, Gözalan A. National Enteric Pathogens Laboratory-based Surveillance Network (UEPLA) in Turkey, July 2007-June 2011, ECCMID Kitabı, Londra (2012). 40. Liu A, Fanning L, Chong H et al. Desensitization regimens for drug allergy: state of the art in the 21st century, Clin Exp Allergy 2011;41(12):1679-89. http://dx.doi.org/10.1111/j.1365-2222.2011.03825.x PMid:21883538 41. Livermore DM, Andrews JM, Hawkey PM et al. Are susceptibility tests enough, or should labora- tories still seek ESBLs and carbapenemases directly?, J Antimicrob Chemother 2012;67(7):1569- 77. 10.1093/jac/dks088. http://dx.doi.org/10.1093/jac/dks088 42. Lloyd DH. Alternatives to conventional antimic- robial drugs: a review of future prospects, Vet Dermatol 2012;23(4):299-304, e59-60. 43. Magpantay G, Cardile AP, Madar CS, Hsue G, Belnap C. Antibiotic desensitization therapy in secondary syphilis and Listeria infection: case reports and review of desensitization therapy, Hawaii Med J 2011;70(12):266-8. PMid:22187514 PMCid:PMC3242422 44. Nakipoğlu Y, Katrancı H, Çağatay A, Derbentli Ş. İstanbul Tıp Fakültesi’nde çeşitli örneklerden izole edilen stafilokok suşlarında glikopeptit direncinin araştırılması, ANKEM Derg 2004;18(4): 208-12. 45. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm!, Trends Mol Med 2012;18(5):263-72. http://dx.doi.org/10.1016/j.molmed.2012.03.003 PMid:22480775 46. Nordmann P, Poirel L, Toleman MA, Walsh TR. Does broad-spectrum beta-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria?, J Antimicrob Chemother 2011;66(4):689- 92. http://dx.doi.org/10.1093/jac/dkq520 PMid:21393184 47. Özkul C, Özçakır O, Uslu N et al. Abstract No.: P08.16 Retrospective evaluation of H. pylori cla- rithromycin resistance in children by Real-Time PCR, Helicobacter 2009;14(4):393. 48. Park B, Liu GY. Targeting the host-pathogen inter- face for treatment of Staphylococcus aureus infec- tion, Semin Immunopathol 2012;34(2):299-315. http://dx.doi.org/10.1007/s00281-011-0297-1 PMid:22089960 49. Poirel L, Heritier C, Tolun V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae, Antimicrob Agents Chemother 2004;48(1):15-22. http://dx.doi.org/10.1128/AAC.48.1.15-22.2004 PMid:14693513 PMCid:PMC310167 50. Poirel L, Ozdamar M, Ocampo-Sosa AA, Turkoglu S, Ozer UG, Nordmann P. NDM-1-producing Klebsiella pneumoniae now in Turkey, Antimicrob Agents Chemother 2012;56(5):2784-5. http://dx.doi.org/10.1128/AAC.00150-12 PMid:22391536 PMCid:PMC3346671 51. Prakash V, Lewis JS 2nd, Jorgensen JH. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibi- lity test method used, Antimicrob Agents Chemother 2008;52(12):4528. http://dx.doi.org/10.1128/AAC.00904-08 PMid:18838599 PMCid:PMC2592869 52. Rice LB. Federal funding for the study of antimic- robial resistance in nosocomial pathogens: no ESKAPE, J Inf ect Dis 2008;197(8):1079-81. http://dx.doi.org/10.1086/533452 PMid:18419525 53. Sancak B. Staphylococcus aureus ve antibiyotik direnci, Mikrobiyol Bul 2011;45(3):565-76. PMid:21935792 54. Sancak B, Ercis S, Menemenlioglu D, Colakoglu S, Hascelik G. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital, J Antimicrob Chemother 2005;56(3):519-23. http://dx.doi.org/10.1093/jac/dki272 PMid:16046461 55. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe, Euro Surveill 2008;13(47):30-40. 56. Türk Dağı H, Arslan U, Tuncer İ. Kan kültürlerin- den izole edilen Acinetobacter baumannii suşla- rında antibiyotik direnci, ANKEM Derg 2011; 25(1):22-6. 57. Türkiye Halk Sağlığı Kurumu. http://tuberkuloz. thsk.gov.tr/index.php?pid=44. Erişim tarihi: 14.07.2013. (2013). 58. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm?, Clin Microbiol Rev 2005;18(2):306-25. http://dx.doi.org/10.1128/CMR.18.2.306-325.2005 PMid:15831827 PMCid:PMC1082798 59. Werner G, Coque TM, Hammerum AM et al. Emergence and spread of vancomycin resistance among enterococci in Europe, Euro Surveill 2008;13(47):8-18. 60. WHO. The evolving threat of antimicrobial resis- tance: Options for action. WHO Press, Geneva, Switzerland (2012). 61. WHO. Global Tuberculosis Report. WHO Press, Geneva, Switzerland (2012). 62. WHO. http://www.who.int/features/2010/ smallpox/en/. Erişim tarihi: 14.07.2013 (2010). 63. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010, MMWR Recomm Rep 2010;59(RR-12):1-110. PMid:21160459 64. Yong D, Toleman MA, Giske CG et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin este- rase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India, Antimicrob Agents Chemother 2009;53(12): 5046-54. http://dx.doi.org/10.1128/AAC.00774-09 PMid:19770275 PMCid:PMC2786356 65. Zarakolu P, Sakızlıgil B, Ünal S. Ankara ilindeki seks çalışanlarından izole edilen Neisseria gonorr- hoeae suşlarının antimikrobiyallere karşı direnç durumu, Mikrobiyol Bul 2006;40(1-2):69-73. PMid:16775959